McIlrath & Eck’s Moderna MRNA Stock Holding History

McIlrath & Eck’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.27K	Hold	25	–	–	﹤0.01%	1466
2025 Q4	$737	Hold	25	–	–	﹤0.01%	938
2025 Q3	$646	Hold	25	–	–	﹤0.01%	906
2025 Q2	$690	Hold	25	–	–	﹤0.01%	888
2025 Q1	$709	Hold	25	–	–	﹤0.01%	883
2024 Q4	$1.04K	Sell	25 -125	-83%	-$5.97K	﹤0.01%	909
2024 Q3	$10K	Buy	150 +50	+50%	+$4.59K	﹤0.01%	626
2024 Q2	$11.9K	Hold	100	–	–	﹤0.01%	568
2024 Q1	$10.7K	Hold	100	–	–	﹤0.01%	589
2023 Q4	$9.95K	Sell	100 -100	-50%	-$8.41K	﹤0.01%	558
2023 Q3	$20.7K	Hold	200	–	–	﹤0.01%	401
2023 Q2	$24.3K	Buy	200 +100	+100%	+$13.3K	0.01%	386
2023 Q1	$15.4K	Hold	100	–	–	﹤0.01%	459
2022 Q4	$18K	Hold	100	–	–	﹤0.01%	427
2022 Q3	$12K	Hold	100	–	–	﹤0.01%	496
2022 Q2	$14K	Hold	100	–	–	﹤0.01%	445
2022 Q1	$17K	Hold	100	–	–	﹤0.01%	430
2021 Q4	$25K	Hold	100	–	–	0.01%	370
2021 Q3	$38K	Hold	100	–	–	0.01%	274
2021 Q2	$23K	Hold	100	–	–	0.01%	365
2021 Q1	$13K	Hold	100	–	–	﹤0.01%	435
2020 Q4	$10K	Buy	+100	New	+$10.1K	﹤0.01%	426
2020 Q2	–	Sell	-335	Closed	-$10K	–	699
2020 Q1	$10K	Buy	+335	New	+$7.71K	0.01%	311

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

McIlrath & Eck's MRNA Position: Q1 2026 in Review

McIlrath & Eck held its Moderna (MRNA) position steady in Q1 2026 at 25 shares worth $1.27K. The position accounts for ﹤0.01% of the portfolio, ranked #1466.

McIlrath & Eck first reported a position in MRNA in Q1 2020 and has held it in 23 quarters since. The position peaked at $38K in Q3 2021. 726 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

McIlrath & Eck held 25 shares of Moderna worth $1.27K as of Q1 2026.
McIlrath & Eck left its Moderna share count unchanged in Q1 2026.
Moderna made up ﹤0.01% of McIlrath & Eck's portfolio in Q1 2026, its #1466 holding.
McIlrath & Eck first reported a position in Moderna in Q1 2020 and has held it in 23 quarters since.
McIlrath & Eck's Moderna position peaked at $38K in Q3 2021.
726 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on McIlrath & Eck's 13F filing for Q1 2026, filed 19 May 2026.